Literature DB >> 10461029

Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender.

S Craft1, S Asthana, G Schellenberg, M Cherrier, L D Baker, J Newcomer, S Plymate, S Latendresse, A Petrova, M Raskind, E Peskind, C Lofgreen, K Grimwood.   

Abstract

Higher fasting plasma insulin levels and reduced CSF-to-plasma insulin ratios, suggestive of insulin resistance, have been observed in patients with Alzheimer's disease (AD) who do not possess an apolipoprotein E (APOE)-epsilon4 allele. We examined the relationship of APOE and gender to peripheral insulin action and hyperinsulinemic memory facilitation in patients with AD using a sensitive measure of insulin-mediated glucose disposal. Participants were 32 patients with AD (9 without an epsilon4 allele, 23 with an epsilon4 allele) and 25 healthy age-matched adults (16 without an epsilon4 allele, 9 with an epsilon4 allele). AD subjects without an epsilon4 allele had significantly lower insulin-mediated glucose disposal rates than AD patients with an epsilon4 allele (p < 0.03), or than normal adults without an epsilon4 allele (p < 0.02). Female AD subjects showed lower insulin-mediated glucose disposal rates than did male AD subjects (p < 0.02). No significant interaction was observed between APOE group and gender, suggesting that these effects are independent. AD subjects without an epsilon4 allele also showed significant memory facilitation in the hyperinsulinemic condition (p < 0.04), whereas the AD-epsilon4 group did not. Also in the hyperinsulinemic condition, AD patients without an epsilon4 allele had lower insulin levels than patients with an epsilon4 allele (p < 0.02), and women with AD had lower insulin levels than did men with AD despite similar insulin infusion rates and body mass (p < 0.004). No gender or genotype effects were observed in either condition for normal subjects. These results provide in vivo evidence of differences in insulin-mediated energy metabolism between epsilon4 and non-epsilon4 AD, and suggest that defective insulin action may be of particular pathophysiologic significance for patients without an epsilon-4 allele.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10461029     DOI: 10.1159/000054469

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  55 in total

1.  Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling.

Authors:  L Gasparini; G K Gouras; R Wang; R S Gross; M F Beal; P Greengard; H Xu
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

Review 2.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  Brain meets body: the blood-brain barrier as an endocrine interface.

Authors:  William A Banks
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

4.  Increased food intake leads to obesity and insulin resistance in the tg2576 Alzheimer's disease mouse model.

Authors:  Motoyuki Kohjima; Yuxiang Sun; Lawrence Chan
Journal:  Endocrinology       Date:  2010-02-22       Impact factor: 4.736

Review 5.  The role of gonadotropins in Alzheimer's disease: potential neurodegenerative mechanisms.

Authors:  Anna M Barron; Giuseppe Verdile; Ralph N Martins
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 6.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Authors:  Sergio T Ferreira; William L Klein
Journal:  Neurobiol Learn Mem       Date:  2011-09-06       Impact factor: 2.877

Review 7.  Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.

Authors:  Konstantinos Ioannis Avgerinos; Grigorios Kalaitzidis; Antonia Malli; Dimitrios Kalaitzoglou; Pavlos Gr Myserlis; Vasileios-Arsenios Lioutas
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

8.  The relationship between fasting serum glucose and cerebral glucose metabolism in late-life depression and normal aging.

Authors:  Christopher M Marano; Clifford I Workman; Christopher H Lyman; Elisse Kramer; Carol R Hermann; Yilong Ma; Vijay Dhawan; Thomas Chaly; David Eidelberg; Gwenn S Smith
Journal:  Psychiatry Res       Date:  2014-02-01       Impact factor: 3.222

9.  Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; Lauren C Costantini
Journal:  Nutr Metab (Lond)       Date:  2009-08-10       Impact factor: 4.169

Review 10.  Hypometabolism as a therapeutic target in Alzheimer's disease.

Authors:  Lauren C Costantini; Linda J Barr; Janet L Vogel; Samuel T Henderson
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.